Literature DB >> 17988800

Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats.

X Zhang1, F Dong, G E Mayer, D C Bruch, J Ren, B Culver.   

Abstract

Neuroinflammatory processes associated with induction of cyclooxygenase (COX) have been implicated in the deleterious events resulting in neurodegeneration. The present study was designed to investigate the impact of acute methamphetamine (MA) administration on COX expression and prostaglandin E2 (PGE(2)) production, and to evaluate the effect of selective COX-2 inhibition using celecoxib in MA-induced degeneration of dopaminergic terminal and cell apoptosis in the striatum. Male Sprague-Dawley rats were treated with either a neurotoxic regimen of methamphetamine hydrochloride (5 mg/kg, i.p., every 2 h for four injections) with or without celecoxib (7.5 mg/kg) or vehicle. COX-1 expression was not affected by MA, while both COX-2 protein expression and number of COX-2 positive cells in striatum were significantly reduced 24 h after MA treatment. However, after 72 h, a significant upregulation of COX-2 protein was detected. PGE(2) production was correlated with altered COX-2 levels. NFkappa-B (NFkappa B), a key regulator of COX-2 expression, was activated 72 h after MA administration, and was accompanied by increased Ikappa B (Ikappa B) phosphorylation. Animals receiving MA exhibited an increase in apoptotic cells and notable reductions in dopamine (DA) content (63.9%) in immunoreactivity of tyrosine hydroxylase (TH) and neuron specific microtubule-associated protein 2 (MAP2) in striatum. Administration of celecoxib exacerbated MA-induced DA depletion, and did not affect MA-induced MAP2 damage, apoptosis or proliferation of glial cells. Our findings suggest that COX-2 containing cells are targets of the damage during earlier stages of MA-related neurotoxicity, and that the selective inhibition of COX-2 enzyme is harmful rather than protective. The COX-2 induction appears during the recovery period, and NFkappa B activation may be an important mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988800     DOI: 10.1016/j.neuroscience.2007.09.059

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Role of microglia in methamphetamine-induced neurotoxicity.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-06-15

Review 2.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

3.  Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.

Authors:  Takeshi Tsuji; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Norio Ogawa
Journal:  Neurochem Res       Date:  2008-10-23       Impact factor: 3.996

4.  [Snitrosylating protein disulphide isomerase mediates increased expression of α synuclein caused by methamphetamine in mouse brain].

Authors:  Yue Wang; Wen-Ning Xu; Xiao-Fang Wu; Lin-Nan Zhu; Hong-Hua Qiao; Ling Chen; Chao Liu; Ping-Ming Qiu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

5.  Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.

Authors:  Hilary Grosso; Jong-Min Woo; Kang-Woo Lee; Joo-Young Im; Eliezer Masliah; Eunsung Junn; M Maral Mouradian
Journal:  FASEB J       Date:  2014-06-26       Impact factor: 5.191

6.  Cyclooxygenase activity contributes to the monoaminergic damage caused by serial exposure to stress and methamphetamine.

Authors:  Nicole A Northrop; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2013-05-02       Impact factor: 5.250

7.  Chronic voluntary oral methamphetamine induces deficits in spatial learning and hippocampal protein kinase Mzeta with enhanced astrogliosis and cyclooxygenase-2 levels.

Authors:  Jorge A Avila; Roseanna M Zanca; Denis Shor; Nicholas Paleologos; Amber A Alliger; Maria E Figueiredo-Pereira; Peter A Serrano
Journal:  Heliyon       Date:  2018-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.